Market accessCompany release

TriSalus Q3 revenue up 11% as FDA clears TriNav Advance and CMS lifts 2027 payment

🇺🇸 TriSalus Life Sciences, Inc. (TLSI) · Tue 10 Nov 2026

The US company reported third-quarter TriNav revenue of $12.9 million, revised its 2026 guidance, and flagged an FDA clearance and final CMS payment changes for 2027.

TriSalus Life Sciences reported its third-quarter 2026 results on 10 November. TriNav revenue was $12.9 million, an 11% rise. The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million.

On the regulatory side, the US Food and Drug Administration has cleared TriNav Advance. The device is intended for pressure-enabled delivery to small distal vessels.

The company also pointed to final payment decisions from the Centers for Medicare & Medicaid Services (CMS) for 2027. The Outpatient Prospective Payment System (OPPS) rate for HCPCS code C8004 rises to about $20,910. CMS also set a national payment of about $13,800 for the office-based lab setting under a new code, G0577.

The source material available to VigiEye was limited to a short summary. It did not include further detail on the clearance, the guidance revision or the reimbursement changes.

What it means for your team

  • Market-access teams should note the 2027 OPPS rate for C8004 (about $20,910) and the new office-based lab code G0577 (about $13,800 nationally) when modelling procedure economics.
  • Regulatory teams tracking pressure-enabled delivery devices should note the FDA clearance of TriNav Advance for small distal vessels.
  • The summary does not say whether the guidance revision was an increase or a decrease. Readers should check the company's full release for the detail.

Company's press release (SEC filing): TriSalus Life Sciences, Inc. ↗

Article written by VigiEye from the official source (TriSalus Life Sciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →